



We claim:

1. A method of treating PMM2-CDG, comprising administering a therapeutically effective amount of an aldose reductase inhibitor to a subject in need thereof.

2. A method of increasing PMM2 enzymatic activity in a subject with PMM2-CDG, comprising administering a therapeutically effective amount of an aldose reductase inhibitor to the subject.

3. The method of any one of claims 1-2, wherein the aldose reductase inhibitor is a compound of Formula (III) or salt thereof.





4. The method of claim 3, wherein the aldose reductase inhibitor is selected from the following or salts thereof




and


5. The method of any one of claims 1-4, wherein the aldose reductase inhibitor is Compound B or a salt thereof.

6. The method of any one of claims 1-2, wherein the aldose reductase inhibitor is a compound of Formula (II) or salt thereof.

7. The method of claim 6, wherein the aldose reductase inhibitor is selected from the following or salts thereof




and


8. The method of claim 7, wherein the aldose reductase inhibitor is Compound A or a salt thereof.

9. The method of any one of claims 1-2, wherein the aldose reductase inhibitor is a compound of any one of Formulas (I)-(VI) or salt thereof.





10. The method of any one of claims 1-9, wherein the subject is a human.

11. An aldose reductase inhibitor for use in the treatment of PMM2-CDG.

12. The use of claim 11, wherein treatment increases PMM2 enzymatic activity in a subject with PMM2-CDG.

13. The use of any one of claims 11-12, wherein the aldose reductase inhibitor is a compound of Formula (III) or salt thereof.





14. The use of claim 13, wherein the aldose reductase inhibitor is selected from the following or salts thereof




and


15. The use of any one of claims 11-14, wherein the aldose reductase inhibitor is Compound B or a salt thereof.

16. The use of any one of claims 11-12, wherein the aldose reductase inhibitor is a compound of Formula (II) or salt thereof.

17. The method of claim 16, wherein the aldose reductase inhibitor is selected from the following or salts thereof




and


18. The method of claim 17, wherein the aldose reductase inhibitor is Compound A or a salt thereof.

19. The method of any one of claims 11-12, wherein the aldose reductase inhibitor is a compound of any one of Formulas (I)-(VI) or salt thereof.